Fierce Pharma July 26, 2024
AbbVie could have the hottest cancer drug launch of 2025 on its hands. That is one takeaway from a recent ZoomRx survey, which found oncologists are more aware of and excited about AbbVie’s telisotuzumab-vedotin (Teliso-V) than any other investigational cancer candidate.
AbbVie shared phase 2 data on Teliso-V, a c-Met-directed antibody-drug conjugate (ADC), in non-small cell lung cancer (NSCLC) late last year. Based on the results, the drugmaker plans to file for accelerated approval in the third quarter with a view to bringing the ADC to market in 2025. Excitement is already building in the oncology community.
ZoomRx found 55% of oncologists are aware of Teliso-V. Almost one-quarter of oncologists named the candidate as one of the three most exciting...
Today's Sponsors
Today's Sponsor